Website Edition: June/July 2012

National Institute of Neurological Disorders and Stroke
Releases Huntington's Disease Common Data Elements

Wendy R. Galpern, MD, PhD, NINDS; Julie C. Stout, PhD, Monash University; Ira Shoulson, MD, Georgetown University

Background on the CDE Project

In 2011, the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health, released the Parkinson's disease Common Data Elements (CDEs), and the Institute is pleased to announce that the development of CDEs for Huntington's disease (HD) is now complete.

The CDE Project is aimed at developing content standards that enable clinical investigators to systematically collect, analyze, and share data across clinical studies. Study start-up can be a time-consuming effort, and often investigators develop their own data collection tools. The availability of CDEs will facilitate the initiation of a study, promote data collection in a consistent format, and enable comparisons between studies. Twelve disorders are currently included in the CDE Project (http://www.commondataelements.ninds.nih.gov), with PD, HD, and Friedreich's ataxia being of particular interest to the Movement Disorders community.

Huntington's Disease CDEs

Process and products

For the HD CDEs, an external Working Group of nearly 60 HD experts world-wide was assembled and divided into 11 Subgroups, with Julie Stout, PhD (Monash University, Melbourne, Australia) and Ira Shoulson, MD (Georgetown University, Washington, DC) serving as the Working Group Chairs.

Subgroups

A listing of the HD CDE Working Group Members is available on the HD CDE website.

The HD Subgroups met over a 15-month period to develop their recommendations. Following an internal Working Group review period, the recommendations were posted for public comment. The feedback was incorporated, and the HD CDEs are now publicly available for use.

On the website, you will find a listing of standardized instruments with recommendations regarding their use. There is a catalog of HD CDEs, template case report forms, and data dictionaries. Subgroups gave particular attention to differences in recommendations for manifest versus pre-manifest HD.

It was recommended that the following instruments be collecting in all HD studies:

Core Recommendations for HD Studies

In addition, as addressed in detail on the website, several other instruments can be considered for use in various types of HD studies.

How to find the CDEs

1. Search the internet for "NINDS HD CDE"

NINDS Common Data Elements

2. Click "Tools" to access the CDE Catalog, CRF Library, and Form Builder

NINDS Common Data Elements Tools

Impact of the CDEs

Rapid adoption of the HD CDEs will translate into improved efficiencies across clinical research activities. The CDEs provide a library of assessments and measurement standards that have been vetted by experts in the field, which will make it increasingly possible to choose measures with confidence even for aspects of HD that are outside of a given investigator's direct areas of expertise. The longer-term benefits of using the HD CDEs will include the ability to create large datasets by combining several studies that share common elements. Such large datasets are required, for example, to be able to detect the very smallest effects that HD has in people many years before onset, and to examine more subtle genetic variability. The HD CDEs will provide investigators, both experienced and new to field, with a valuable research tool to access and make use of informative data elements that have stood the test of time in assessing individuals affected by HD.

References

  1. Huntington Study Group. The Unified Huntington's Disease Rating Scale: Reliability and Consistency. Mov Dis, 1996; 11:136-142.
  2. Craufurd D, Thompson J, Snowden JS. Behavioural changes in Huntington's disease: The Problem Behaviours Assessment. Neuropsychiatry, Neuropsychology and Behavioural Neurology, 2001; 14(4):219-226.
  3. Rowe KC, et al. Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology, 2010; 24(4):435-442.
  4. Bechtel, N., Scahill, R. I., Rosas, H. D., Acharya, van den Bogaard, S.J.A., Jauffret, C., Say, M.J., Sturrock, A., Johnson, H., Onorato, C.E., Salat, D.H., Durr, A., Leavitt, B.R., Roos, R.A.C., Landwehrmeyer, B., Langbehn, D. R., Stout, J.C., Tabrizi, S.J., Reilmann, R. Tapping linked to function and structure in premanifest and symptomatic Huntington's disease. Neurology, 2010; 75:2150-2160.
  5. Stroop, J. R. Studies of interference in serial verbal reactions. Journal of Experimental Psychology: General, 1935; 18:643-662.
  6. Smith A. Symbol digit modalities test: Manual. Los Angeles; Western Psychological Services; 1982.
  7. Fals-Stewart W. An Interrater Reliability Study of the Trail Making Test (Parts A and B). Perceptual and Motor Skills, 1992; 74:39-42.
  8. Paulsen, J. S., Wang, C., Duff, K., Barker, R., Nance, M., Beglinger, L. et al. Challenges assessing clinical endpoints in early Huntington disease. Mov Disord, 2010; 25(15):2595-2603.
  9. Marder, K., et al., Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology, 2000; 54(2):452-8.